Department of Surgery, St Marks Hospital, Middlesex, UK.
Colorectal Dis. 2013 Feb;15(2):224-30. doi: 10.1111/j.1463-1318.2012.03125.x.
Early identification of patients experiencing postoperative complications is imperative for successful management. C-reactive protein (CRP) is a nonspecific marker of inflammation used in many specialties to monitor patient condition. The role of CRP measurement early in the elective postoperative colorectal patient is unclear, particularly in the context of enhanced recovery (ERAS).
Five hundred and thirty-three consecutive patients who underwent elective colorectal surgery between October 2008 and October 2010 within an established ERAS programme were studied. Patients were separated into a development group of 265 patients and a validation group of 268 patients by chronological order. CRP and white cell count were added to a prospectively maintained ERAS database. The primary outcome of the study was all adverse events (including infective complications, postoperative organ dysfunction and prolonged length of stay) during the initial hospital admission. Significant predictors for adverse events on univariate analysis were submitted to multivariate regression analysis and the resulting model applied to the validation group. The validity and predictive accuracy of the regression model was assessed using receiver operating characteristic curve/area under the curve (AUC) analysis.
CRP levels >150 mg/l on postoperative day 2 and a rising CRP on day 3 were independently associated with all adverse events during the hospital admission. A weighted model was applied to the validation group yielding an AUC of 0.65 (95% CI 0.58-0.73) indicating, at best, modest discrimination and predictive accuracy for adverse events.
Measurement of CRP in patients after elective colorectal surgery in the first few days after surgery within ERAS can assist in identifying those at risk of adverse events and a prolonged hospital stay. A CRP value of >150 mg/l on day 2 and a rising CRP on day 3 should alert the surgeon to an increased likelihood of such events.
早期识别术后并发症患者对于成功管理至关重要。C 反应蛋白(CRP)是一种非特异性炎症标志物,广泛应用于多个医学领域以监测患者病情。CRP 在接受择期结直肠手术后患者中的作用尚不清楚,尤其是在加速康复(ERAS)背景下。
我们研究了 2008 年 10 月至 2010 年 10 月期间在既定 ERAS 计划内接受择期结直肠手术的 533 例连续患者。患者按时间顺序分为 265 例的开发组和 268 例的验证组。CRP 和白细胞计数被添加到前瞻性维护的 ERAS 数据库中。该研究的主要结局是初始住院期间的所有不良事件(包括感染性并发症、术后器官功能障碍和住院时间延长)。单变量分析中显著的不良事件预测因素被提交给多变量回归分析,并将得到的模型应用于验证组。使用接受者操作特征曲线/曲线下面积(AUC)分析评估回归模型的有效性和预测准确性。
术后第 2 天 CRP 水平>150mg/l 和第 3 天 CRP 升高与住院期间的所有不良事件独立相关。验证组应用加权模型,AUC 为 0.65(95%CI 0.58-0.73),表明在最佳情况下,对不良事件的区分度和预测准确性仅为中等。
在 ERAS 内,对接受择期结直肠手术后的患者在术后最初几天内测量 CRP 有助于识别发生不良事件和延长住院时间的风险患者。第 2 天 CRP 水平>150mg/l 和第 3 天 CRP 升高应提醒外科医生发生此类事件的可能性增加。